MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 564208 | Name: Flobetapir
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Flobetapir is a blood-brain barrier crossing ligand of amyloid protein deposits in the brain.

Chemical Structure

Flobetapir
Flobetapir
CAS#938435-69-9

Theoretical Analysis

MedKoo Cat#: 564208

Name: Flobetapir

CAS#: 938435-69-9

Chemical Formula: C20H25FN2O3

Exact Mass: 360.1849

Molecular Weight: 360.43

Elemental Analysis: C, 66.65; H, 6.99; F, 5.27; N, 7.77; O, 13.32

Price and Availability

Size Price Availability Quantity
25mg USD 450.00 2 Weeks
100mg USD 1,250.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
AV45; AV 45; AV-45; Flobetapir; Florbetapir; Flobetair
IUPAC/Chemical Name
4-[(E)-2-[6-[2-[2-(2-fluoroethoxy)ethoxy]ethoxy]pyridin-3-yl]ethenyl]-N-methylaniline
InChi Key
YNDIAUKFXKEXSV-NSCUHMNNSA-N
InChi Code
InChI=1S/C20H25FN2O3/c1-22-19-7-4-17(5-8-19)2-3-18-6-9-20(23-16-18)26-15-14-25-13-12-24-11-10-21/h2-9,16,22H,10-15H2,1H3/b3-2+
SMILES Code
CNC1=CC=C(/C=C/C2=CC=C(OCCOCCOCCF)N=C2)C=C1
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 360.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Florbetapir F 18. 2020 Aug 17. PMID: 29999779. 2: Lowe SL, Duggan Evans C, Shcherbinin S, Cheng YJ, Willis BA, Gueorguieva I, Lo AC, Fleisher AS, Dage JL, Ardayfio P, Aguiar G, Ishibai M, Takaichi G, Chua L, Mullins G, Sims JR. Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. J Prev Alzheimers Dis. 2021;8(4):414-424. doi: 10.14283/jpad.2021.56. PMID: 34585215. 3: Okamura N, Yanai K. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. IDrugs. 2010 Dec;13(12):890-9. PMID: 21154149. 4: Meng H, Zheng S, Yuan S, Zhou Q, Gao Y, Ni Y, He L, Yin D, Zhang M, Chen S. Hybrid 18F-florbetapir PET/MRI for assessing myelin recovery in GFAP-A patients. Transl Neurosci. 2022 Jun 9;13(1):120-124. doi: 10.1515/tnsci-2022-0223. PMID: 35795195; PMCID: PMC9186510. 5: Carotenuto A, Giordano B, Dervenoulas G, Wilson H, Veronese M, Chappell Z, Polychronis S, Pagano G, Mackewn J, Turkheimer FE, Williams SCR, Hammers A, Silber E, Brex P, Politis M. [18F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis. Eur J Nucl Med Mol Imaging. 2020 Feb;47(2):366-378. doi: 10.1007/s00259-019-04533-y. Epub 2019 Oct 21. PMID: 31637481; PMCID: PMC6974490. 6: Asghar M, Hinz R, Herholz K, Carter SF. Dual-phase [18F]florbetapir in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):304-311. doi: 10.1007/s00259-018-4238-2. Epub 2018 Dec 19. PMID: 30569187; PMCID: PMC6333719. 7: Planton M, Saint-Aubert L, Raposo N, Payoux P, Salabert AS, Albucher JF, Olivot JM, Péran P, Pariente J. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study. J Alzheimers Dis. 2020;73(4):1607-1614. doi: 10.3233/JAD-190625. PMID: 31958082; PMCID: PMC7081105. 8: Martínez G, Vernooij RW, Fuentes Padilla P, Zamora J, Bonfill Cosp X, Flicker L. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2. PMID: 29164603; PMCID: PMC6486090. 9: Raposo N, Planton M, Péran P, Payoux P, Bonneville F, Lyoubi A, Albucher JF, Acket B, Salabert AS, Olivot JM, Hitzel A, Chollet F, Pariente J. Florbetapir imaging in cerebral amyloid angiopathy-related hemorrhages. Neurology. 2017 Aug 15;89(7):697-704. doi: 10.1212/WNL.0000000000004228. Epub 2017 Jul 19. PMID: 28724587. 10: Trembath L, Newell M, Devous MD Sr. Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir. J Nucl Med Technol. 2015 Sep;43(3):175-84. doi: 10.2967/jnmt.115.156679. Epub 2015 Aug 13. PMID: 26271806. 11: Soffers F, Ceyssens S, Buffet W, de Surgeloose D, Crols R. 18F-Florbetapir PET in Primary Cerebral Amyloidoma. Clin Nucl Med. 2020 Oct;45(10):838-839. doi: 10.1097/RLU.0000000000003214. PMID: 32796236. 12: Hauser SL, Josephson SA, Johnston SC. Florbetapir: knowing one's future. Ann Neurol. 2012 Jun;71(6):A6. doi: 10.1002/ana.23646. PMID: 22718551. 13: Gaubert S, Raimondo F, Houot M, Corsi MC, Naccache L, Diego Sitt J, Hermann B, Oudiette D, Gagliardi G, Habert MO, Dubois B, De Vico Fallani F, Bakardjian H, Epelbaum S; Alzheimer’s Disease Neuroimaging Initiative. EEG evidence of compensatory mechanisms in preclinical Alzheimer's disease. Brain. 2019 Jul 1;142(7):2096-2112. doi: 10.1093/brain/awz150. PMID: 31211359. 14: Moscoso A, Silva-Rodríguez J, Aldrey JM, Cortés J, Pías-Peleteiro JM, Ruibal Á, Aguiar P; Alzheimer’s Disease Neuroimaging Initiative. 18F-florbetapir PET as a marker of myelin integrity across the Alzheimer's disease spectrum. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1242-1253. doi: 10.1007/s00259-021-05493-y. Epub 2021 Sep 28. PMID: 34581847; PMCID: PMC8921113. 15: Gurol ME, Becker JA, Fotiadis P, Riley G, Schwab K, Johnson KA, Greenberg SM. Florbetapir-PET to diagnose cerebral amyloid angiopathy: A prospective study. Neurology. 2016 Nov 8;87(19):2043-2049. doi: 10.1212/WNL.0000000000003197. Epub 2016 Sep 7. PMID: 27605173; PMCID: PMC5109947. 16: Golla SS, Verfaillie SC, Boellaard R, Adriaanse SM, Zwan MD, Schuit RC, Timmers T, Groot C, Schober P, Scheltens P, van der Flier WM, Windhorst AD, van Berckel BN, Lammertsma AA. Quantification of [18F]florbetapir: A test-retest tracer kinetic modelling study. J Cereb Blood Flow Metab. 2019 Nov;39(11):2172-2180. doi: 10.1177/0271678X18783628. Epub 2018 Jun 13. PMID: 29897009; PMCID: PMC6826855. 17: Lilleker JB, Hodgson R, Roberts M, Herholz K, Howard J, Hinz R, Chinoy H. [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann Rheum Dis. 2019 May;78(5):657-662. doi: 10.1136/annrheumdis-2018-214644. Epub 2019 Feb 13. PMID: 30760470; PMCID: PMC6517800. 18: Khor YM, Cuddy S, Harms HJ, Kijewski MF, Park MA, Robertson M, Hyun H, Di Carli MF, Bianchi G, Landau H, Yee A, Sanchorawala V, Ruberg FL, Liao R, Berk J, Falk RH, Dorbala S. Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1998-2009. doi: 10.1007/s00259-019-04627-7. Epub 2019 Dec 5. PMID: 31807884; PMCID: PMC8202062. 19: Gibson GE, Luchsinger JA, Cirio R, Chen H, Franchino-Elder J, Hirsch JA, Bettendorff L, Chen Z, Flowers SA, Gerber LM, Grandville T, Schupf N, Xu H, Stern Y, Habeck C, Jordan B, Fonzetti P. Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial. J Alzheimers Dis. 2020;78(3):989-1010. doi: 10.3233/JAD-200896. PMID: 33074237; PMCID: PMC7880246. 20: Hake A, Trzepacz PT, Wang S, Yu P, Case M, Hochstetler H, Witte MM, Degenhardt EK, Dean RA; Alzheimer's Disease Neuroimaging Initiative. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Alzheimers Dement. 2015 Aug;11(8):986-93. doi: 10.1016/j.jalz.2015.03.002. Epub 2015 Apr 24. PMID: 25916563; PMCID: PMC4544658.